ArticleFrontiers in pharmacology2024
Yinqin Qingfei granules alleviate
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Citrulline drives age-related lipid deposition for healthspan.Nature communications · 2026Article
- Characteristics and influencing factors of bronchoalveolar lavage fluid cellular patterns in children withTranslational pediatrics · 2026Article
- Correlation analysis of FABP3, MCP-4, and CXCL9 levels and myocardial damage in patients with severe pneumonia.Journal of medical biochemistry · 2026Article
- Comparative progress on the mechanisms of airway mucosal injury induced by different pathogens: SARS-CoV-2, influenza A virus, and Mycoplasma pneumoniae.Frontiers in cellular and infection microbiology · 2026Review
- Impact of early corticosteroid therapy on short-term pulmonary function and clinical outcomes in children with severeFrontiers in pediatrics · 2026Article
- The value of serum CARDS toxin and NETs formation in children with MPP.Frontiers in cellular and infection microbiology · 2026Article
- Determination of FAT-1 desaturase activity and substrate preference.Journal of lipid research · 2025Article
- Andrographolide AlleviatesIranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: The primary components of YQQFG were identified using LC-MS/MS. Results: 25 effective components with favorable oral bioavailability were identified in YQQFG. Both Conclusion: YQQFG mitigates inflammatory responses by suppressing NLRP3 inflammasome-mediated macrophage pyroptosis, thereby ameliorating MP-induced acute lung injury. YQQFG serves as an effective adjunct and alternative medication for pediatric MPP treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.